Eton Pharmaceuticals price to free cash flow ETON

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: 97.0×
4-year median: 38.7×
Against its 4-year history: 79th; percentile: 0 is its lowest day, 100 its highest
4-year range: 9.8× to 493×
Peer median: 8.9×

Eton Pharmaceuticals' price to free cash flow is 97.0× as of Oct 23, 2026.

That is above its 4-year median of 38.7×, higher than on 79% of days in the last 4 years.

Over that time it ranged from 9.8× in Nov 2023 to 493× in May 2025.

The median for 10 large drugmakers of a similar size is 8.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	97.0×	18.8×	123×
2025	21.5×	20.6×	493×
2024	160×	11.5×	166×
2023	12.1×	9.8×	50.0×

Against its peers

Companies in Drug Manufacturers - General nearest Eton Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
ETONEton Pharmaceuticals	97.0×
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	7.0×
HRMYHarmony Biosciences	n/m
PBHPrestige Consumer Healthcare	9.6×
ABUSArbutus Biopharma	n/m
COLLCollegium Pharmaceutical	2.3×
Peer median	8.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Eton Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.